Revelatio™ — From the Latin: "an unveiling; the disclosure of what was previously hidden."
When Recovery Fails: Breaking the Downward Spiral of Ocular Surface Disease.
Most patients with ocular surface disease improve with treatment. But some do not — and understanding why requires a fundamentally different framework. Chronic Ocular Surface Dysbiosis explores the conditions under which the ocular surface loses its capacity for self-correction, the ecological and immunologic factors that perpetuate disease, and the clinical strategies that can interrupt the downward spiral. This is not a course about adding another drop. It is a course about understanding why the surface fails to recover — and what that means for how we treat.
The clinician who understands dysbiosis sees the refractory dry eye patient differently. Rather than escalating through a formulaic treatment ladder, they ask: what is preventing recovery? What has disrupted the ecological balance of this surface? What conditions are sustaining the inflammatory cycle? These questions lead to better clinical decisions — and better outcomes for the patients who need it most.
A Note on This Experience
This educational experience challenges the conventional treatment-ladder approach to ocular surface disease. It is designed for clinicians who want to understand why their most difficult patients are not improving — and what to do about it.
Course Details
Credit hours and COPE approval pending. Join the waitlist to receive notification when this course becomes available.
Upon successful completion of this educational experience, the clinician will be able to:
Define ocular surface dysbiosis and distinguish it from conventional models of dry eye disease pathogenesis.
Explain the ecological and immunologic mechanisms that perpetuate chronic ocular surface disease and prevent recovery.
Identify clinical features that suggest dysbiotic rather than simply inflammatory ocular surface disease.
Apply an ecosystem-restoration framework to the management of refractory ocular surface disease.
Recognize the clinical relationships between Demodex, the lid margin microbiome, meibomian gland dysfunction, and chronic surface instability.
This educational experience is organized into the following modules. Content is subject to refinement prior to final release.
From gut to ocular surface — what dysbiosis means, why it matters, and how it reframes our understanding of chronic disease.
The tear film, lid margin, conjunctiva, and cornea as an integrated ecological system — and what happens when that system loses stability.
Why some ocular surfaces fail to recover despite appropriate treatment — the biological mechanisms that perpetuate disease and resist intervention.
The lid margin microbiome, Demodex ecology, and the role of microbial dysbiosis in sustaining chronic ocular surface disease.
A clinical framework for restoring ocular surface stability — moving beyond symptom suppression to address the conditions that perpetuate disease.
Translating the dysbiosis framework into clinical decisions — patient assessment, therapeutic sequencing, and outcome evaluation.
Educational Philosophy
This educational experience is designed to support clinical reasoning and evidence-informed decision-making. It does not constitute clinical advice and should not replace consultation of official prescribing information, applicable standards of care, or the clinical judgment of the treating clinician. COPE approval and credit hours are pending and will be confirmed prior to release.
Join the waitlist for Chronic Ocular Surface Dysbiosis and receive notification when this educational experience becomes available.
Companion Resource
Explore the therapeutic reference library designed to support the clinical reasoning developed in MYODCE educational experiences.
Explore the Companion